•65 Herpes AEs
–MVC QD 25 AEs in 18 (4.3%) subjects
–MVC BID 32 AEs in 29 (6.8%) subjects
–Placebo 8 AEs in 8 (3.8%) subjects
–
•19 Category C
Herpes-related AEs
–MVC QD 11 AEs in 10 (2.4%) subjects
–MVC BID 6 AEs in 6 (1.4%) subjects
–Placebo 2 AEs in 2 (1.0%) subjects